调强放疗联合多西他赛和尼妥珠单抗治疗食管癌的疗效观察  

Effect of intensity- modulated radiotherapy combined with docetaxel and nimotuzumab in treatment of patients with esophageal carcinoma

作　　者：罗海涛[1] 梁彩霞[1] 

机构地区：[1]南方医科大学附属南海医院肿瘤科,广东佛山528200

出　　处：《现代肿瘤医学》2015年第2期219-222,共4页Journal of Modern Oncology

摘　　要：目的:评价调强放疗联合多西他赛和尼妥珠单抗治疗食管癌的疗效和安全性。方法:55例不能手术或拒绝手术的中晚期食管癌患者根据入选标准随机分成调强放疗联合每周多西他赛和尼妥珠单抗(治疗组)和同期放化疗(对照组),治疗组在调强放疗的同时给予多西他赛20-30mg/m2,静脉滴注,尼妥珠单抗200mg,静脉滴注,每周1次,连续6周,在放疗第一天同时进行。两组化疗和调强放疗方法相同。结果:治疗组与对照组完全缓解率(CR)分别为53.8%和46.2%,有效率(CR+PR)分别为84.6%和73.1%。1、2、3年局控率分别为85.7%、67.9%、57.1%和70.4%、63.0%、51.9%;生存率分别为71.4%、53.6%、39.3%和63.0%、40.7%、29.6%。治疗组近期毒副反应尤其是放射性食管炎及Ⅰ、Ⅱ度骨髓抑制较对照组大,有1例因放射性食管炎中断治疗,其他经处理后均能顺利完成治疗。远期并发症以食管狭窄为主,两组无明显差异。结论:调强放疗联合每周多西他赛和尼妥珠单抗治疗较同期放化疗组疗效好,可提高中晚期食管癌的近期和中远期疗效,且毒副反应患者能耐受。Objective：To evaluate the clinical efficacy and safely of concurrent intensity-modulated radiotherapy combined with docetaxel and nimotuzumab in treatment of patients with esophageal carcinoma.Methods：All 55 patients with locally advanced esophageal cancer were randomly divided into the concurrent chemoradiotherapy and nimotuzumab group （28 patients） and the concurrent chemotherapy and radiotherapy group （27 patients）.The radiotherapy and docetaxe treatment were the same in the two groups.Nimotuzumab was given to patients concurrently in the treadted group.Results：The response rates and complete response in the treadted group group were significantly higher than those in the control group.The acute toxic effect was severer in concurrent chemoradiotherapy and nimotuzumab group than in concurrent chemotherapy and radiotherapy group.Conclusion：The intensity-modulated radiotherapy concurrently combined with docetaxel and nimotuzumab for patients with inoperable esophageal cancer is effective,and the patients could tolerate the side effects.

关 键 词：食管癌 调强放射治疗 尼妥珠单抗 多西他赛 同期放化疗 

分 类 号：R735.1[医药卫生—肿瘤]